Magic mushroom compound tested for stubborn OCD

NCT ID NCT06299319

Ongoing Symptom relief Sponsor: Centre for Addiction and Mental Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This small early-phase study is testing whether psilocybin, the active ingredient in magic mushrooms, combined with supportive therapy can safely help people with obsessive-compulsive disorder (OCD) that hasn't responded to standard treatments. Ten adults with treatment-resistant OCD will receive two 25 mg doses of psilocybin two weeks apart. The study focuses on safety, feasibility, and changes in OCD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin (the active ingredient in magic mushrooms)
What this could lead to: If this works, it could point toward a new treatment option for people with obsessive-compulsive disorder that hasn't improved with standard therapies.
What could go wrong: This is a very early, small trial with only 10 participants and no placebo group. Results may not apply to everyone, and psilocybin can cause temporary psychological distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Locations

Centre for Addiction and Mental Health

Toronto, Ontario, M6J 1H1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.